Claims
- 1. A synthetic apolipoprotein E-mimicking peptide, comprising:
a receptor binding domain of apolipoprotein E; and a lipid-associating peptide, wherein said receptor binding domain is covalently linked to said peptide.
- 2. The synthetic apolipoprotein E-mimicking peptide of claim 1, wherein said lipid-associating peptide is model class A amphipathic helical peptide 18A.
- 3. The synthetic apolipoprotein E-mimicking peptide of claim 1, wherein said receptor binding domain of apolipoprotein E having an amino acid sequence selected from the group consisting of SEQ ID Nos. 1-3.
- 4. The synthetic apolipoprotein E-mimicking peptide of claim 1, wherein said apolipoprotein E is from a species selected from the group consisting of human, mouse, rabbit, monkey, rat, bovine, pig and dog.
- 5. The synthetic apolipoprotein E-mimicking peptide of claim 1, wherein said synthetic peptide is N-terminally protected using acetyl and amino groups.
- 6. The synthetic apolipoprotein E-mimicking peptide of claim 1, wherein said peptide enhances low density lipoprotein (LDL) binding to and degradation by cells.
- 7. The synthetic apolipoprotein E-mimicking peptide of claim 6, wherein said cells are fibroblast cells.
- 8. The synthetic apolipoprotein E-mimicking peptide of claim 1, wherein said peptide enhances very low density lipoprotein (VLDL) binding to and degradation by cells.
- 9. The synthetic apolipoprotein E-mimicking peptide of claim 8, wherein said cells are hepatocytes.
- 10. A pharmaceutical composition, comprising the synthetic apolipoprotein E-mimicking peptide of claim 1 and a pharmaceutically acceptable carrier.
- 11. A method of enhancing low density lip oprotein (LDL) binding to a cell in an individual, comprising the step of:
contacting said cell with the pharmaceutical composition of claim 10.
- 12. The method of claim 11, wherein said pharmaceutical composition is administered in an amount of about 0.01 mg/kg to about 100 mg/kg.
- 13. A method of enhancing very low density lipoprotein (VLDL) binding to a cell in an individual, comprising the step of:
contacting said cell with the pharmaceutical composition of claim 10.
- 14. The method of claim 13, wherein said pharmaceutical composition is administered in an amount of about 0.01 mg/kg to about 100 mg/kg.
- 15. A method of increasing low density lipoprotein (LDL) degradation by a cell in an individual, comprising the step of:
contacting said cell with the pharmaceutical composition of claim 10.
- 16. The method of claim 15, wherein said pharmaceutical composition is administered in an amount of about 0.01 mg/kg to about 100 mg/kg.
- 17. A method of increasing very low density lipoprotein (VLDL) degradation by a cell in an individual, comprising the step of:
contacting said cell with the pharmaceutical composition of claim 10.
- 18. The method of claim 17, wherein said pharmaceutical composition is administered in an amount of about 0.01 mg/kg to about 100 mg/kg.
- 19. A method of lowering low density lipoprotein (LDL) cholesterol in an individual in need of such treatment, comprising the step of:
administering to said individual with the pharmaceutical composition of claim 10.
- 20. The method of claim 19, wherein said pharmaceutical composition is administered in an amount of about 0.01 mg/kg to about 100 mg/kg.
- 21. A method of lowering very low density lipoprotein (VLDL) cholesterol in an individual in need of such treatment, comprising the step of:
administering to said individual with the pharmaceutical composition of claim 10.
- 22. The method of claim 21, wherein said pharmaceutical composition is administered in an amount of about 0.01 mg/kg to about 100 mg/kg.
- 23. A method of treating an individual with atherosclerosis, comprising the step of:
administering to said individual with the pharmaceutical composition of claim 10.
- 24. The method of claim 23, wherein said pharmaceutical composition is administered in an amount of about 0.01 mg/kg to about 100 mg/kg.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 09/271,066 filed Mar. 17, 1999, which claims benefit of provisional patent application U.S. Ser. No. 60/078,229 filed Mar. 17, 1998, now abandoned.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60078229 |
Mar 1998 |
US |
|
60078229 |
Mar 1998 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09271066 |
Mar 1999 |
US |
Child |
09520698 |
Mar 2000 |
US |